NSE/ACUTAAS

ACUTAASACUTAAS

NSE Equity · NSE

₹2,361.7+0.91%

52-wk low52-WEEK RANGE52-wk high

₹1,086.4+117.4% from low ·-7.7% from high₹2,558.6

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

ACUTAAS+110.02% · 1Y

Range high ₹2,634.8Range low ₹1,059Latest ₹2,361.7218 bars · daily-close · NSE bhavcopy + 10Y history

NSE EquitySpecialty ChemicalsMidcapLow Risk

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite75/100

Performance

High

Amongst the strong performers in the market.

· 52w return +110.0% — strong momentum
· Trades 40.5% above 200-DMA — uptrend intact

Valuation

High

Looks expensive vs the sector.

· P/E 67.8 — 174% above sector median 24.8
· P/B 13.73 above sector median

Growth

High

Growing faster than the broader market.

· Revenue YoY +40.3% — strong top-line
· Profit YoY +225.8% — strong earnings growth

Profitability

High

Showing good signs of profitability & efficiency.

· ROE 20.3% — high-quality compounder
· Net margin 15.8% — strong pricing power

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeB(61/100)

Durability

A+

92/100

Financially resilient — strong quality + solvency profile.

Show 2 drivers

Debt/Equity0.01 (100pt)
ROE20.3% (81pt)

Valuation

3/100

Richly valued on most axes; limited margin of safety.

Show 4 drivers

P/E vs sector (67.8 / 24.8)274% (5pt)
P/B13.73 (0pt)
Dividend yield0.06% (2pt)
EV/EBITDA50.1 (0pt)

Momentum

A+

87/100

Strong, confirmed momentum across price + technicals.

Show 5 drivers

52w change+110.0% (100pt)
DMA-trend alignmentstrong up (100pt)
RSI (14)54.1 (60pt)
Price vs 200-DMA+39.8% (100pt)
MACD regimebearish (30pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)67.83

FAIR

CheapestP/E 67.8 near sector median.Most expensive

P/B13.73

OVERVALUED

CheapestP/B 13.73 at 87th %ile of sector.Most expensive

EV/EBITDA50.05

OVERVALUED

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 5

High-quality compounder (ROE 20.3%)
Above 20% ROE consistently flags capital-efficient businesses
Lean balance sheet (D/E 0.01)
Low leverage means earnings are less sensitive to rate cycles
Consistent top-line growth (24.6% 3Y CAGR)
Sustained revenue compounding is rare and hard to fake
Strong net margin (15.8%)
High margin indicates pricing power + operating efficiency
Top quartile ROE in Other
Rank 128 of 1000 peers

WEAKNESSES · 1

Premium to sector on P/E (+174%)
P/E 67.8 vs Other median 24.8

OPPORTUNITIES · 1

Strong uptrend — DMA stack bullish
Price > 20-DMA > 50-DMA > 200-DMA: momentum tailwind intact

THREATS · 1

Valuation compression risk
P/E 67.8 is 174% above sector — any growth miss gets punished

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+0.9%

-0.0%

+13.3%

+36.0%

+71.0%

+110.0%

—

10Y

—

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
ACUTAASTHIS Acutaas Chemicals Limited	₹2,361.7	—	19,408	67.8	13.73	20.3%	0.01	+40.3%
ABCAPITAL Aditya Birla Capital Limited	₹340.4	+68.1%	89,888	25.8	2.79	10.8%	4.60	+17.6%
ABBOTINDIA Abbott India Limited	₹25,785	-16.6%	54,547	35.8	13.60	38.0%	0.04	+9.6%
360ONE 360 ONE WAM LIMITED	₹1,113.3	+16.7%	44,744	38.7	4.77	12.3%	1.47	+35.0%
3MINDIA 3M India Limited	₹31,410	+4.4%	35,158	92.9	21.83	23.5%	0.06	+6.1%
AADHARHFC Aadhar Housing Finance Limited	₹496.45	+3.5%	21,173	20.8	3.05	14.6%	2.55	—
ABDL Allied Blenders and Distillers Limited	₹573.8	+76.4%	16,176	60.4	10.70	17.7%	0.67	+5.8%
AAVAS Aavas Financiers Limited	₹1,347.9	-37.8%	10,612	17.1	2.26	13.3%	3.08	+13.3%
63MOONS 63 moons technologies limited	₹662.7	-9.8%	8,006	—	0.92	-0.2%	0.00	-6.3%

ASK AXEL

Dig deeper into ACUTAAS

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for ACUTAAS — all in one sourced reply.

Ask free in chat

Run these tools on ACUTAAS

Historical return →

"If I had bought ACUTAAS in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on ACUTAAS

Brokerage + charges →

All-in cost for trading ACUTAAS

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	9.05	13.10	+44.8%
-2q	9.00	8.82	-2.0%
-3q	3.95	5.41	+37.0%
-4q	6.17	7.80	+26.3%

ACUTAASACUTAAS

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Analyst consensus

Company + balance sheet snapshot

Peer comparison · Other

Ask Axel about ACUTAAS

Recent news

Dig deeper into ACUTAAS

Run these tools on ACUTAAS

Technical snapshot

Earnings history + surprises

Dividends + splits history

Recent news

Stock scorecard

SWOT analysis

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Fundamentals

Pros and cons

Sector-relative context

Analyst consensus

Company + balance sheet snapshot

Peer comparison · Other